Appl. No. 371 of PCT/US2005/011046 Amdt. dated September 29, 2006 Preliminary Amendment

## Amendments to the Claims:

The following list of claims will replace all prior versions, and listings of claims in the application.

Claims 1-257 (canceled).

258. (new) A method of treating a patient with a cancerous tumor, the method comprising co-administering to the patient: (i) a thymidilate synthase (TS) inhibitor in combination with 5,10 methylene tetrahydrofolate; and, (ii) an anti-VEGF antibody, wherein the TS inhibitor and the anti-VEGF antibody are administered in dosage amounts effective to reduce the volume of the tumor.

- 259. (new) The method of claim 258, wherein the TS inhibitor is 5-fluorouracil (5-FU) or an analogue or prodrug of 5-FU.
- 260. (new) The method of claim 259, wherein the TS inhibitor is administered intravenously, or by injection, or orally.
- 261. (new) The method of claim 259, wherein the TS inhibitor is 5-FU and the dosage amount of the 5-FU is from about 100 milligrams to about 1 gram per m<sup>2</sup>.
- 262. (new) The method of claim 259, wherein the prodrug is N4-pentyloxylcarbonyl -5'-deoxy-5-fluorocytidine (capecitabine).
- 263. (new) The method of claim 262, wherein the dosage amount of the capecitabine is from about 1000 mg to about 5 grams per m<sup>2</sup>.

Appl. No. 371 of PCT/US2005/011046 Amdt. dated September 29, 2006 Preliminary Amendment

264. (new) The method of claim 258, wherein the 5,10 methylene tetrahydrofolate is administered in-travenously or by injection.

265. (new) The method of claim 258, wherein the dosage amount of the 5,10 methylene tetrahydrofolate is from about 50 milligrams to about 250 milligrams per m<sup>2</sup>.

266. (new) The method of claim 258, wherein the tumor is colorectal cancer, breast cancer, gastric cancer, non-small-cell lung cancer, cervical cancer, ovarian cancer, pancreatic cancer, esophageal cancer, or head-and-neck cancer.

267. (new) The method of claim 258, wherein the anti-VEGF antibody is bevacizumab (Avastin).

administration.

268. (new) A method of treating a patient with a cancerous tumor, the method comprising co-administering to the patient the following combination of drugs:

- (i) N4-pentyloxylcarbonyl-5'-deoxy-5-fluorocytidine (capecitabine);
- (ii) 5,10 methylene tetrahydrofolate; and
- (iii) at least one additional chemotherapeutic agent selected from the group consisting of:

an alkylating agent, an antimetabolite, a topoisomerase inhibitor, a microtubule disrupting drug, a nucleic acid synthesis inhibitor, a kinase inhibitor, a hormone blocking drug, a proteosome inhibitor, a vascularization inhibitor, an immune modulator, an anti-inflammatory, a cytokine, an inhibitor of a cytokine, a receptor-binding drug, and a 5-fluorouracil modulator; wherein the combination of drugs are administered in dosage amounts effective to reduce the volume of the tumor.

- 269. (new) The method of claim 268 wherein the cancer being treated is colorectal cancer, breast cancer, gastric cancer, non-small-cell lung cancer, cervical cancer, ovarian cancer, pancreatic cancer, esophageal cancer, or head-and-neck cancer.
- 270. (new) The method of claim 268, wherein the at least one additional chemotherapeutic agent is a specific binding member, or a nucleic acid or a nucleic acid analogue molecule, or a small molecule.
- 271. (new) The method of claim 270, wherein said specific binding member comprises an antibody that binds a growth factor.
- 272. (new) The method of claim 271, wherein said antibody that binds a growth factor is at least one antibody that binds VEGF.
- 273. (new) The method of claim 272, wherein the antibody the binds VEGF is bevacizumab.
- 274. (new) The method of claim 271, wherein the antibody that binds a growth factor is at least one antibody that binds EGFR.
- 275. (new) The method of claim 274, wherein the antibody that binds EGFR is cetuximab.
- 276. (new) The method of claim 268, wherein the at least one additional chemotherapeutic agent is selected from the group comprising: irinotecan (CPT-11), difluorodeoxycytidine (gemcitabine), (E)-2'-deoxy-2'-(fluoromethylene) cytidine (tezacitabine), doxorubicin, epirubicin, mitomycin C, cyclophosphamide, cisplatin, oxaliplatin, paclitaxel, docetaxel, vincristine, vinblastine and vinorelbine.
- 277. (new) The method of claim 268, wherein the combination of drugs are are formulated separately.

Appl. No. 371 of PCT/US2005/011046 Amdt. dated September 29, 2006 Preliminary Amendment

**PATENT** 

278. (new) The method of claim 268, wherein combination of drugs is formulated for oral administration.